期刊文献+

磷霉素联合不同抗菌药物对多重耐药鲍曼不动杆菌的体外药物敏感试验研究 被引量:9

原文传递
导出
摘要 目的评价磷霉素分别与亚胺培南、米诺环素、阿米卡星、头孢哌酮/舒巴坦、替加环素、多黏菌素B联合用药,对于临床分离的多重耐药鲍曼不动杆菌的体外联合抗菌效应。方法分离多重耐药鲍曼不动杆菌临床株30株,采用微量肉汤稀释棋盘法测定不同浓度组合的抗菌药物单用及联合应用对30株耐药鲍曼不动杆菌的最低抑菌浓度(minimum inhibitory concentration,MIC),并计算分数抑菌浓度指数(fractional inhibitory concentration index,FICI)判定联合效应。结果磷霉素分别与亚胺培南、米诺环素、阿米卡星、头孢哌酮/舒巴坦、替加环素、多黏菌素B联合应用后,FICI≤0.5的菌株分别占56.7%(17/30)、36.7%(11/30)、10.0%(3/30)、6.7%(2/30)、6.7%(2/30)和6.7%(2/30);FICI>0.5,且≤1分别占43.3%(13/30)、63.3%(19/30)、43.3%(13/30)、50.0%(15/30)、56.7%(17/30)和60.0%(18/30);FICI>1,且<4分别占0、0、46.7%(14/30)、43.3%(13/30)、36.7%(11/30)和33.3%(10/30);FICI≥4的菌株比例均为0。亚胺培南、米诺环素、阿米卡星和头孢哌酮/舒巴坦分别与磷霉素联合后,50%最低抑菌浓度(MIC50)分别下降为单用时的1/16、1/8、1/8、1/4;90%最低抑菌浓度(MIC90)分别下降为单用时的1/8、1/4、1/8、1/2。替加环素与多黏菌素B联用磷霉素后MIC50/MIC90值均未见明显改变。结论磷霉素可以不同程度降低所联合应用抗菌药物的MIC,以亚胺培南和米诺环素最为明显,阿米卡星、头孢哌酮/舒巴坦次之。替加环素与多黏菌素B因本身敏感性较高,协同和叠加作用不明显。以上联合实验均未出现拮抗反应。
出处 《中华传染病杂志》 CAS CSCD 2019年第6期356-359,共4页 Chinese Journal of Infectious Diseases
  • 相关文献

参考文献6

二级参考文献100

  • 1Liu H Y,Lin H C,Lin Y C,et al. Antimicrobial susceptibilities of urinary extended-spectrum beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol lmmunol Infect, 2011,44(5):364-368.
  • 22010年中国CHINET细菌耐药性监测.
  • 3Ribes S,Taberner F,Domenech A,et al. Evaluation of fosfomycin alone and in combination with ceftriaxone or vaneomycin in an experimental model of meningitis caused by two strains of cephalosporinresistant Streptococcus pneumoniae. J Antimicrob Chemother, 2006,57:931-936.
  • 4Banon Arias R,Garcia Lopez M,Pinedo Sanchez A. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae. J Chemother, 2001,13:535-540.
  • 5Butcu M, Akcay SS, Inan AS, et al. In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics. J Infect Chemother,2011,17(4):575-578.
  • 6Sun C,Falagas ME,Wang R. In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo), 2011,64(8):559-62.
  • 7Falagas ME,Vouloumanou EK,Togias AG,et al. Fosfomycin versus other antibiotics for the treatment of cystitis:ameta-analysis of randomized controlled trials. J Antimicrob Chemother, 2010,65 : 1862-77.
  • 8Pullukcu H,Tasbakan M,Sipahi OR,et al. Fosfomycin in the treatment of extended spectrum beta-laetamase- producing Eschericbia coli-related lower urinary tract infections. Int J Antimicrob Agents, 2007,29:62-65.
  • 9Rodriguez-Bano J,Alcala JC,Cisneros JM,et al. Community infections caused by extended-spectrum beta-lactamase-produc-ing Escherichia coll. Arch Intern Med, 2008,168 :1897-1902.
  • 10Jones RN,Anderegg TR,Swenson JM. Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin(polymyxin E)by standardizedmethods. J Clin Microbiol,2005,43:925-927.

共引文献1062

同被引文献97

引证文献9

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部